![Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire](https://mms.businesswire.com/media/20190706005001/en/731417/22/LOGO_NEW_PF_QUADRI_2007.jpg)
Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire
![ESMO-BC 2022: Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+ / HR+ early breast cancer (eBC) ESMO-BC 2022: Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+ / HR+ early breast cancer (eBC)](https://larvolclin.s3.us-west-2.amazonaws.com/resize_165156826914208392386270ee8de88fb.png)
ESMO-BC 2022: Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+ / HR+ early breast cancer (eBC)
Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected
Sheree Feigelson, Cranford, New Jersey professional. Expert Benefits Coordinator at J.F. Kiely Construction Co. Family of Companies | Ladders Expert Network
Manpower et Pierre Fabre engagés en faveur des travailleurs handicapés | #Emploi & #Handicap : "Avec Manpower nous nous rejoignons sur les valeurs humaines qui sont celles de Laboratoires Pierre Fabre". Découvrez
![PharmaShots Interview: Pierre Fabre' Roberta Valenti Shares Insights on Nerlynx (neratinib) for the Treatment of HER2 Early Breast Cancer PharmaShots Interview: Pierre Fabre' Roberta Valenti Shares Insights on Nerlynx (neratinib) for the Treatment of HER2 Early Breast Cancer](https://pharmashots.com/public/images/20220427193835_original_39.webp)